LPL Financial LLC lifted its position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 82.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,668 shares of the company’s stock after purchasing an additional 6,164 shares during the period. LPL Financial LLC’s holdings in 10x Genomics were worth $763,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the company. BlackRock Inc. raised its stake in 10x Genomics by 14.2% in the first quarter. BlackRock Inc. now owns 9,156,992 shares of the company’s stock worth $696,572,000 after buying an additional 1,138,358 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of 10x Genomics by 1.8% during the first quarter. Baillie Gifford & Co. now owns 8,753,987 shares of the company’s stock valued at $488,385,000 after purchasing an additional 151,752 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of 10x Genomics by 5.7% during the third quarter. Vanguard Group Inc. now owns 8,274,359 shares of the company’s stock valued at $235,654,000 after purchasing an additional 446,601 shares in the last quarter. FMR LLC increased its stake in shares of 10x Genomics by 36.5% during the first quarter. FMR LLC now owns 4,372,294 shares of the company’s stock valued at $243,930,000 after purchasing an additional 1,169,928 shares in the last quarter. Finally, Sands Capital Management LLC increased its stake in shares of 10x Genomics by 16.6% during the first quarter. Sands Capital Management LLC now owns 3,737,768 shares of the company’s stock valued at $208,530,000 after purchasing an additional 530,985 shares in the last quarter. 79.16% of the stock is currently owned by hedge funds and other institutional investors.
10x Genomics Trading Up 3.0 %
Shares of TXG stock opened at $43.42 on Tuesday. 10x Genomics, Inc. has a 12-month low of $31.28 and a 12-month high of $63.57. The firm’s 50 day moving average is $40.46 and its 200 day moving average is $49.52. The stock has a market capitalization of $5.13 billion, a P/E ratio of -22.73 and a beta of 1.84.
Insider Buying and Selling
Analyst Ratings Changes
A number of equities analysts have weighed in on TXG shares. Barclays decreased their target price on shares of 10x Genomics from $66.00 to $47.00 and set an “overweight” rating for the company in a research note on Friday, September 29th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $70.00 target price on shares of 10x Genomics in a research note on Tuesday, September 19th. Citigroup raised their price target on shares of 10x Genomics from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, August 4th. Finally, Morgan Stanley reissued an “overweight” rating and set a $65.00 price target on shares of 10x Genomics in a research report on Monday, August 7th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, 10x Genomics presently has an average rating of “Moderate Buy” and an average price target of $60.78.
10x Genomics Profile
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.
- Five stocks we like better than 10x Genomics
- How to Effectively Use the MarketBeat Ratings Screener
- The most upgraded stocks in November have two things in common
- Compound Interest and Why It Matters When Investing
- Monday.com rocked earnings like it’s the weekend
- High Flyers: 3 Natural Gas Stocks for March 2022
- Plan to own one retailer? Make it this one
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.